<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220636</url>
  </required_header>
  <id_info>
    <org_study_id>SLR-04-028</org_study_id>
    <nct_id>NCT00220636</nct_id>
  </id_info>
  <brief_title>Abilify as an Adjunctive Treatment for Refractory Depression</brief_title>
  <official_title>Abilify (Aripiprazole) as an Adjunctive Treatment for Refractory Unipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical
      antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI)
      antidepressant treatment for depressed outpatients who are not responding fully to SSRI
      treatment alone. It is hypothesized that patients' functioning will improve after 12 weeks of
      treatment with Aripiprazole and SSRI medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study of the effectiveness of adding Abilify (aripiprazole), an atypical
      antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI)
      antidepressant treatment for depressed outpatients who are not responding fully to SSRI
      treatment alone. Fifteen subjects will be given aripiprazole in a flexible dosing schedule
      and followed for 12 weeks, while continuing their ongoing SSRI medication. Assessments of
      depressive symptoms, overall functioning, social functioning, and side effects will be
      completed. It is hypothesized that patients' functioning will improve after 12 weeks of
      treatment with Aripiprazole and SSRI medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinician rated measure of depression, mean score; this study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7) Outcome is the number of these subjects whose depression &quot;responded&quot; after treatment with aripiprazole, which means a 50% or greater decrease in Hamilton Depression Rating Scale scores at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Improvement Scale (CGI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>clinician rated improvement, score on CGI scale ranging from 1 (very much improved) to 7 (very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Assessment of Functioning Scale (GAFS)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Ranging from 0 to 100, with higher score indicating better global functioning. Outcome is the post-treatment GAFS score compared to the pre-treatment GAFS score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beck Depression Inventory (BDI) Score</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.
Outcome is the subject's total BDI score post-treatment compared to the subject's total BDI score pre-treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole 5 to 30 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients between the ages of 18 and 70.

          -  Patients with a principal Diagnostic and Statistical Manual fourth edition (DSM-IV)
             diagnosis of Major Depressive Disorder, unipolar, nonpsychotic type

          -  Patients with a total of 14 or higher on the 17-item Hamilton Depression Scale at
             baseline

          -  Patients who have had treatment with an SSRI at an adequate dose (see Table for a
             minimum of 6 weeks (i.e. 6 wks at the dose defined as adequate in Table 2)

          -  Patients who agree to use acceptable method of birth control throughout the study

        Exclusion Criteria:

          -  Patients with any of the following DSM-IV diagnoses: Delirium, Dementia, Amnestic, or
             other Cognitive Disorders. Bipolar Disorder or cyclothymia, Schizophrenia, Delusional
             (Paranoid) Disorders and Psychotic Disorders not elsewhere classified, Severe
             Borderline Personality Disorder, Anorexia Nervosa, or Bulimia.

          -  Patients who, within the past 6 months, met DSM-IV criteria for abuse of or dependence
             on any drug, including alcohol.

          -  Patients who are pregnant or nursing women.

          -  Patients who would pose a serious risk for suicide during the course of the study, as
             evidenced by one of the following: (a) report of having a specific plan for killing
             themselves, (b) a score of 3 or higher on the Hamilton Depression Rating Scale item #3
             as rated by the treating clinician at Week 0, or (c) a suicide attempt within the last
             6 months which required medical attention, such as an emergency room visit or which is
             considered by the treating physician to have been possibly life threatening

          -  Patients with unstable medical conditions such as untreated or uncontrolled
             hyperthyroidism, hypothyroidism, hypertension (defined as blood pressure&gt;150/90),
             cardiovascular disease, diabetes, HIV (by report of patient).

          -  Patients with a history of seizures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Hellerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NY State Psychiatric Institute, and St. Luke's - Roosevelt Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Evaluation Service, NY State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.DepressionNY.com</url>
    <description>Web Site for the Mood Disorders Research Program, with information about the study and the process of getting involved in research in general and specifically at our site</description>
  </link>
  <reference>
    <citation>Hellerstein DJ. Aripiprazole as an adjunctive treatment for refractory major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1347-8.</citation>
    <PMID>15588762</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>April 15, 2009</results_first_submitted>
  <results_first_submitted_qc>February 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2015</results_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depression</keyword>
  <keyword>Depression</keyword>
  <keyword>Unipolar Depression</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <keyword>Adjunctive treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole</title>
          <description>aripiprazole augmentation treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole</title>
          <description>aripiprazole augmentation treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale (HDRS)</title>
        <description>Clinician rated measure of depression, mean score; this study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7) Outcome is the number of these subjects whose depression &quot;responded&quot; after treatment with aripiprazole, which means a 50% or greater decrease in Hamilton Depression Rating Scale scores at week 12.</description>
        <time_frame>12 weeks</time_frame>
        <population>Adults with treatment resistant depression, all subjects with data after baseline (14 of 15 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>aripiprazole augmentation treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HDRS)</title>
          <description>Clinician rated measure of depression, mean score; this study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7) Outcome is the number of these subjects whose depression &quot;responded&quot; after treatment with aripiprazole, which means a 50% or greater decrease in Hamilton Depression Rating Scale scores at week 12.</description>
          <population>Adults with treatment resistant depression, all subjects with data after baseline (14 of 15 subjects).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis would be no change in the HDRS score pre- to post- treatment with aripiprazole.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=13</method_desc>
            <param_type>t statistic</param_type>
            <param_value>4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions Improvement Scale (CGI)</title>
        <description>clinician rated improvement, score on CGI scale ranging from 1 (very much improved) to 7 (very much worse)</description>
        <time_frame>12 weeks</time_frame>
        <population>all subjects for whom data was available after beginning aripiprazole augmentation (14 of 15 subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>aripiprazole augmentation treatment for treatment resistant depression</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions Improvement Scale (CGI)</title>
          <description>clinician rated improvement, score on CGI scale ranging from 1 (very much improved) to 7 (very much worse)</description>
          <population>all subjects for whom data was available after beginning aripiprazole augmentation (14 of 15 subjects)</population>
          <units>units on CGI scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global Assessment of Functioning Scale (GAFS)</title>
        <description>Ranging from 0 to 100, with higher score indicating better global functioning. Outcome is the post-treatment GAFS score compared to the pre-treatment GAFS score.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>All subjects (14/15) for whom data was available after starting aripiprazole augmentation</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>aripiprazole augmentation treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Assessment of Functioning Scale (GAFS)</title>
          <description>Ranging from 0 to 100, with higher score indicating better global functioning. Outcome is the post-treatment GAFS score compared to the pre-treatment GAFS score.</description>
          <population>All subjects (14/15) for whom data was available after starting aripiprazole augmentation</population>
          <units>points on GAFS scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis would be no change in the GAFS score pre- to post- treatment with aripiprazole.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.009</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=13</method_desc>
            <param_type>t statistic</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beck Depression Inventory (BDI) Score</title>
        <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.
Outcome is the subject's total BDI score post-treatment compared to the subject's total BDI score pre-treatment.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Number of participants for whom data was available after starting aripiprazole augmentation</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>aripiprazole augmentation treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beck Depression Inventory (BDI) Score</title>
          <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.
Outcome is the subject's total BDI score post-treatment compared to the subject's total BDI score pre-treatment.</description>
          <population>Number of participants for whom data was available after starting aripiprazole augmentation</population>
          <units>points on BDI scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis would be no change in the BDI score pre- to post- treatment with aripiprazole.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.008</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>df=13</method_desc>
            <param_type>t statistic</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks, during and after the clinical trial</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole</title>
          <description>aripiprazole augmentation treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open label study without comparison group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Hellerstein MD</name_or_title>
      <organization>NY State Psychiatric Institute</organization>
      <phone>6467748000</phone>
      <email>hellers@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

